Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial.

被引：0
|
作者：
Soto, C. [1 ]
Torrecillas, L. [1 ]
Reyes, S. [1 ]
Ramirez, M. [1 ]
Perez, L. [1 ]
Cervantes, G. [1 ]
Gonzalez, F. [1 ]
Tellez, E. [1 ]
Cortes, P. [1 ]
Benitez, H. [1 ]
机构：
[1] ISSSTE, IMSS, Mexico City, DF, Mexico
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20S / 20S
页数：1
相关论文
共 50 条
  • [41] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Li, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [42] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (PTS) with HER2-positive metastatic breast cancer (MBC)
    Xu, Ligong
    Song, Santai
    Zhu, Jianxin
    Luo, Rongcheng
    Li, Lejing
    Jiao, Sunchang
    Chen, Li
    Tao, Min
    Su, Yongqian
    Liu, Duanqi
    ANNALS OF ONCOLOGY, 2006, 17 : 76 - 77
  • [43] A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses
    Kaufman, Peter Andrew
    Cortes, Javier
    Awada, Ahmad
    Yelle, Louise
    Perez, Edith A.
    Wanders, Jantien
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A Phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)
    Xu, L.
    Song, S.
    Zhu, J.
    Lu, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
  • [45] Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, H. J.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    De Braud, F.
    Haller, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [46] Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin or capecitabine: A Phase Ill, open-label, randomized study
    Cortes, J.
    Awada, A.
    Kaufmann, P. A.
    Yelle, L.
    Perez, E. A.
    Velikova, G.
    Wanders, J.
    Olivo, M.
    He, Y.
    Ductus, C.
    Simons, R.
    Bischoff, J.
    Twelves, C.
    ONKOLOGIE, 2013, 36 : 97 - 97
  • [47] Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC):: A prospective, randomized multicentre phase III study of the AGO breast cancer study group.
    Lueck, H.
    Minckwitz, G. V.
    Du Bois, A.
    Schrader, I.
    Huober, J.
    Heilmann, V.
    Beckmann, M.
    Stähle, A.
    Jackisch, C.
    Marth, C.
    Richter, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 7S - 7S
  • [48] Lucitanib for the treatment of HR+HER2-metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial
    Hui, R.
    Pearson, A.
    Cortes Castan, J.
    Campbell, C.
    Poirot, C.
    Azim, H. A., Jr.
    Fumagalli, D.
    Lambertini, M.
    Daly, F.
    Arahmani, A.
    Perez-Garcia, J.
    Aftimos, P. G.
    Bedard, P.
    Xuereb, L.
    Loibl, S.
    Loi, S.
    Pierrat, M-J.
    Turner, N. C.
    Andre, F.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 93 - 93
  • [49] Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048)
    Valero, V.
    Bosserman, L. D.
    Yardley, D. A.
    Roche, H. H.
    Thomas, E.
    Vahdat, L. T.
    Mukhopadhyay, P.
    Opatt, D. M.
    Peck, R. A.
    Sparano, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials
    Xu, Liang
    Wu, Xiaobo
    Hu, Chun
    Zhang, Zhiying
    Zhang, Le
    Liang, Shujing
    Xu, Yingchun
    Zhang, Fengchun
    ONCOTARGETS AND THERAPY, 2016, 9 : 4061 - 4074
12345